Quarterly report [Sections 13 or 15(d)]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)

v3.26.1
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Net loss $ 3,377,179 $ 2,834,405
Reportable Segment, Aggregation before Other Operating Segment [Member]    
Segment Reporting [Line Items]    
Preclinical, clinical trial and other costs 1,423,041 1,197,035
Research and development personnel expense [1] 386,168 391,505
General and administrative personnel expense [2] 676,382 673,779
Administrative and facilities expense [3] 845,623 584,671
Other income, net [4] 45,965 (12,585)
Net loss $ 3,377,179 $ 2,834,405
[1] Research and development personnel costs include employee stock-based compensation expense of $17,144 and $46,720 for the three months ended March 31, 2026 and 2025, respectively.
[2] General and administrative personnel costs include employee stock-based compensation expense of $52,387 and $122,655 for the three months ended March 31, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC.
[3] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
[4] Other income, net consists of interest and dividend income, unrealized loss on our digital asset, and other miscellaneous income.